Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
<p>Abstract</p> <p>The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radioth...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-01-01
|
| Series: | Radiation Oncology |
| Online Access: | http://www.ro-journal.com/content/3/1/5 |